What's Happening?
bioAffinity Technologies, a biotechnology company specializing in noninvasive diagnostics, announced a significant increase in sales for its CyPath® Lung diagnostic test. In the first quarter of 2026, unit sales grew by 146% compared to the same period
in 2025. This growth reflects increased physician adoption and clinical use of the test, which is designed to aid in lung cancer risk assessment and management of pulmonary nodules. The CyPath® Lung test uses flow cytometry and artificial intelligence to provide a binary result indicating the likelihood of malignancy, thus supporting clinical decision-making. The test is particularly valuable for detecting lung cancer at its earliest, most treatable stage, and for avoiding unnecessary invasive procedures when results are negative.
Why It's Important?
The surge in sales of the CyPath® Lung test highlights a growing demand for noninvasive diagnostic tools in the U.S. healthcare market, which is valued at $3.58 billion for pulmonary nodule management and lung cancer surveillance. The test addresses a critical need for more accurate and less invasive methods of diagnosing lung cancer, a disease with a high mortality rate if not detected early. The increase in sales suggests that more physicians are recognizing the test's potential to improve patient outcomes by facilitating early detection and reducing the need for risky procedures. This trend could lead to broader adoption of similar technologies, potentially transforming lung cancer diagnostics and treatment strategies.
What's Next?
bioAffinity Technologies plans to continue expanding the clinical impact of its CyPath® Lung test. The company is focusing on increasing the number of ordering physician sites and integrating the test into clinical workflows. Additionally, bioAffinity is conducting a large-scale longitudinal clinical study to further validate the test's effectiveness. The company is also exploring broader applications of its technology platform, including diagnostic tests for other lung diseases such as asthma and COPD. These initiatives aim to solidify the test's position in the market and drive further growth in sales and clinical adoption.
